Summary
Introduction
Since the identification of the first point mutations associated with the mitochondrial encephalomyopathies (Wallace et al., 1988; Goto et al., 1990; Kobayashi et al., 1990; Shoffner et al., 1990) , Ͼ30 different base-pair substitutions have been linked to an increasingly diverse group of progressive and debilitating neurological diseases (Wallace, 1992; Wallace et al., 1993; Johns, 1995) . Despite the clinical diversity, many patients with inherited mitochondrial encephalopathies are found to have one of two specific mutations of mitochondrial DNA (mtDNA): an A to G transition at nucleotide position 3243 of the L-strand (light-strand), or an A to G transition at position 8344 of the L-strand. Although these two mutations are both genetically and phenotypically distinct, A3243G and A8344G are considered to be representative of many other mitochondrial transfer RNA (tRNA) gene mutations on a molecular and a clinical level.
The A3243G mutation was originally described in a patient with MELAS (mitochondrial encephalomyopathy and lactic acidosis with stroke-like episodes), which is characterized by recurrent stroke-like episodes, migraine, nausea and vomiting. Chronic progressive external ophthalmoplegia (CPEO), diabetes mellitus, myopathy, cardiomyopathy and gastrointestinal dysfunction are also associated with this mutation (Ciafaloni et al., 1992) . On the other hand, the A8344G mutation was originally described in association with MERRF (myoclonic epilepsy with red ragged fibres), which presents with progressive myoclonic epilepsy, ataxia and myopathy, although optic atrophy, peripheral neuropathy, hearing loss and dementia have also been reported .
The clinical features that accompany these two mutations are highly variable, not only in terms of the age of onset and the severity of symptoms, but also in relation to the specific organs involved . Therefore, although many patients who harbour the A3243G mutation suffer recurrent strokes and epilepsy in early adult life, many others have diabetes or a mild myopathy (Hammans et al., 1995) . Likewise, although myoclonus and ataxia are commonly associated with the A8344G mutation, oligosymtomatic individuals have also been documented (Hammans et al., 1993; Howell et al., 1996) . This extreme variability can be explained, at least in part, by the complex genetic basis of these two disorders. Individuals with A3243G and A8344G carry both mutant and wild type (normal) mtDNA within each cell (heteroplasmy) (Wallace, 1992; . In vitro studies with cybrid cell lines have shown that both A3243G and A8344G cause a mitochondrial respiratory chain defect and impair intramitochondrial protein synthesis, providing that a specific threshold (~85%) of mutant mtDNA is exceeded (Chomyn et al., 1991; Kobayashi et al., 1991; Boulet et al., 1992; King et al., 1992) . Because the level of mutant mtDNA varies between individuals, and also between organs and tissues within an individual, it is generally accepted that the variation in the proportion of mutant mtDNA (percentage mutation load) is the principal factor responsible for the varied clinical expression of the mtDNA defects (Holt et al., 1990; Ciafaloni et al., 1991; Macmillan et al., 1993) . However, previous studies have found only a weak correlation between mutation load and clinical phenotype (Kobayashi et al., 1992; Martinuzzi et al., 1992; Shiraiwa et al., 1993; Liou et al., 1994; Campos et al., 1995) . Although this discrepancy may be explained in part by inter-cellular heteroplasmy, other unidentified factors, environmental or genetic, may play a substantial role in the modulation of the primary mtDNA defect (Sparaco et al., 1993; Tanno et al., 1993; Hammans et al., 1995) .
The inherent complexity of mtDNA segregation and phenotypic expression has made it very difficult to give useful clinical information to individuals who harbour these defects. We therefore designed this study to increase our understanding of the genotype-phenotype relationships for mtDNA point mutations, and thereby to improve the clinical advice that we give to our patients. We asked two key questions. First, what is the frequency of specific clinical features associated with the A3243G and A8344G mutations? Secondly, is there a clear relationship between the level of mutant mtDNA and clinical phenotype? Our analyses confirm that the frequency of key clinical features is different for the A3243G and A8344G mutations, and we also identified a significant association between the level of mutant mtDNA in muscle and the frequency of the more common clinical features.
Methods
Individuals who harbour the A3243G mutation (Ciafaloni et al., 1991; Obermaier-Kusser et al., 1991; Ciafaloni et al., 1992; Martinuzzi et al., 1992; Chen et al., 1993; Hamazaki et al., 1993; Koo et al., 1993; Macmillan et al., 1993; Moraes et al., 1993; Mosewich et al., 1993; Onishi et al., 1993; Shanske et al., 1993; Degoul et al., 1994; de Vries et al., 1994; Dougherty et al., 1994; Kawakami et al., 1994; Liou et al., 1994; Campos et al., 1995; Damian et al., 1995; Hammans et al., 1995; Hsu et al., 1995; Huang et al., 1995 Huang et al., , 1996 Mariotti et al., 1995; Rusanen et al., 1995; Tanno et al., 1995; Campos et al., 1996; Fabrizi et al., 1996; Li et al., 1996; Ohno et al., 1996; Verma et al., 1996; Yamamoto, 1996) and the A8344G mutation (Shoffner et al., 1990; Seibel et al., 1991; Boulet et al., 1992; Larsson et al., 1992; Lertrit et al., 1992; Graf et al., 1993; Hammans et al., 1993; Piccolo et al., 1993; Silvestri et al., 1993; Tanno et al., 1993; Calabresi et al., 1994; Fang et al., 1994; Ozawa et al., 1995; Traff et al., 1995; Chen et al., 1996) were identified from our own clinical database and through a computer search of the scientific literature. The clinical data and laboratory methods were closely scrutinized before entering information into the database. We did not include studies with either an incomplete clinical description (one study excluded on this basis). Following this, the percentage level of mutant mtDNA in blood (specifically the leukocyte/platelet fraction) and/or skeletal muscle was recorded, and the presence or absence of specific clinical features was noted. We made no attempt to grade the severity of each clinical feature.
The frequencies of clinical features associated with the two mutations were compared by χ 2 analysis with Yates' correction for 2ϫ2 contingency tables. Only clinical features which were observed at Ͼ15% frequency were analysed further. For both blood and muscle values, individual cases were categorized into 10 groups according to the percentage level of mutant mtDNA. The frequencies of the clinical features in subjects with different levels of mutant mtDNA in blood and muscle were then compared by χ 2 analysis for a trend (χ 2 TR ) (Altman, 1991) . Odds ratios were calculated with confidence intervals (CIs) for the clinical features which reached statistical significance with the χ 2 TR test (Daly et al., 1991) .
Results

Frequency of clinical features associated with A3243G MELAS and A8344G MERRF
We identified 245 individuals with the A3243G or A8344G mutations measured in skeletal muscle (for A3243G, n ϭ 111; for A8344G, n ϭ 55), and/or blood (for A3243G, n ϭ 73; for A8344G, n ϭ 25).
A3243G
The observed frequencies for each clinical feature were as follows: recurrent strokes 48%; CPEO 28%; diabetes mellitus 15%; pigmentary retinopathy 15%; deafness 44%; dementia 27%; epilepsy 50%; myopathy 53%; short stature 15%; lipomata 1%; optic atrophy 1%; neuropathy 5%; ataxia 24%; and myoclonus 8% (Fig. 1) . Three patients were noted to have gastrointestinal features (malabsorption and/or dysmotility), three were noted to have a cardiomyopathy, and three had extrapyramidal features.
A8344G
The observed frequencies of each of the clinical features described above were as follows: recurrent strokes 1%; CPEO 6%; diabetes mellitus 3%; pigmentary retinopathy 0%; deafness 39%; dementia 25%; epilepsy 43%; myopathy 70%; short stature 13%; lipomata 8%; optic atrophy 13%; neuropathy 24%; ataxia 50%; and myoclonus 61%. χ 2 analysis revealed statistically significant differences between A3243G and A8344G for the frequency of the following clinical features: recurrent strokes (χ 2 ϭ 53.27, P ϭ 2.91ϫ10 -13 ); CPEO (χ 2 ϭ 15.29, P ϭ 9.22ϫ10 -5 ); diabetes mellitus (χ 2 ϭ 8.24, P ϭ 0.0041); pigmentary retinopathy (χ 2 ϭ 12.90, P ϭ 0.0003); myopathy (χ 2 ϭ 6.62, P ϭ 0.0101); lipomata (χ 2 ϭ 6.71, P ϭ 0.0094); optic atrophy (χ 2 ϭ 19.01, P ϭ 1.3ϫ10 -5 ); neuropathy (χ 2 ϭ 19.63, P ϭ 9.4ϫ10 -6 ); ataxia (χ 2 ϭ 17.14, P ϭ 3.47ϫ10 -5 ); and myoclonus (χ 2 ϭ 81.19, P ϭ 2.05ϫ10 -19 ). The first four abnormalities were more frequent in A3243G patients whereas the last six were more frequent in A8344G patients. No significant differences were detected for deafness, dementia, epilepsy or short stature.
Frequency of clinical features and mutant load A3243G
No clear relationship was observed between the level of A3243G in blood and the frequency of any of the clinical features (n ϭ 73, data not shown). In contrast, for the clinical features which occurred in Ͼ15% of cases of A3243G, the frequency of each feature was correlated to the level of mutant mtDNA in muscle (n ϭ 111, Fig. 2A and B) . For example, the observed frequency of recurrent strokes rose from zero in individuals with 21-40% A3243G in muscle (n ϭ 9) to 94% for individuals with 91-100% in muscle (n ϭ 19),(χ 2 TR ϭ 16.50, P ϭ 4.85ϫ10 -5 ). The frequency of dementia rose from 11% in individuals with 21-60% A3243G in muscle (n ϭ 27) to 37% in individuals with 91-100% in muscle (n ϭ 19) (χ 2 TR ϭ 5.30, P ϭ 0.0213). The frequency of epilepsy rose from 34% for individuals with 21-60% A3243G in muscle (n ϭ 27) to 94% for individuals with 81-100% A3243G in muscle (n ϭ 19) (χ 2 TR ϭ 10.50, P ϭ 0.0012); and the frequency of ataxia rose from 11% in individuals with 21-40% A3243G in muscle (n ϭ 9) to 42% in individuals with 91-100% in muscle (n ϭ 19) (χ 2 TR ϭ 4.35, P ϭ 0.0369).
In contrast, we identified an inverse correlation between mutation load and clinical phenotype for other features. For example, 56% of individuals with 31-40% A3243G in muscle had CPEO (n ϭ 7), whereas only 5% with 81-100% A3243G in muscle had CPEO (n ϭ 19) (χ 2 TR ϭ 11.64, P ϭ 0.0006). Similarly, 89% of individuals with 31-40% A3243G in muscle had myopathy (n ϭ 7), whereas only 32% with 81-100% A3243G in muscle had a myopathy (n ϭ 19) (χ 2 TR ϭ 9.10, P ϭ 0.0025); and although 86% of individuals with 41-50% A3243G in muscle had deafness (n ϭ 5), 21% with 91-100% A3243G in muscle were deaf (n ϭ 19) (χ 2 TR ϭ 8.81, P ϭ 0.0033).
Odds risk ratios were calculated for the clinical features which reached statistical significance with the χ 2 TR test. Individuals with Ͼ90% mutant mtDNA in muscle were 9.5 times more likely to have recurrent strokes (95% CI ϭ 3.20-28.04) and 2.1 times more likely to have epilepsy (95% CI ϭ 1.35-3.37) than individuals with ഛ40% mutant mtDNA in muscle. Similarly, individuals with Ͼ90% mutant mtDNA in muscle were 3.8 times more likely to have ataxia (95% CI ϭ 1.08-13.25), and 3.3 times more likely to have dementia (CI ϭ 1.19-9.20) than individuals with ഛ40% mutant mtDNA in muscle. The 95% CIs of the odds ratio for deafness data set included unity. In contrast, individuals with Ͼ90% mutant mtDNA in muscle were 2.9 times less likely to have myopathy (95% CI ϭ 1.44-5.55) and 10.64 times less likely to have CPEO (95% CI ϭ 2.73-40.98) than individuals with ഛ40% mutant mtDNA in muscle. 
A8344G
No clear relationship was observed between the level of A8344G in blood and the frequency of any one clinical feature (n ϭ 25, data not shown). In contrast, for the clinical features which occurred in Ͼ15% of cases of A8344G, the frequency of each feature increased with higher levels of mutant mtDNA in muscle (n ϭ 55, Fig. 2C ). For example, not one individual with 51-80% A8344G in muscle was deaf (n ϭ 8), whereas 52% of individuals with 91-100% A8344G in muscle were deaf (n ϭ 25) (χ 2 TR ϭ 6.93, P ϭ 0.0085). Similarly, no individuals with 51-80% A8344G in muscle had dementia (n ϭ 8), whereas 32% of individuals with 91-100% A8344G in muscle were demented (n ϭ 25) (χ 2 TR ϭ 4.57, P ϭ 0.0326). Whereas 38% of individuals with 51-80% A8344G in muscle had epilepsy (n ϭ 8), 64% of individuals with 91-100% A8344G in muscle had epilepsy (n ϭ 25) (χ 2 TR ϭ 1.27, n.s.). Whereas 62% of individuals with 51-80% A8344G in muscle had a myopathy (n ϭ 8), 76% of individuals with 91-100% A8344G in muscle had a myopathy (n ϭ 25) (χ 2 TR ϭ 0.01, n.s.). Whereas 25% of individuals with 51-80% A8344G in muscle had a neuropathy (n ϭ 8), 32% of individuals with 91-100% A8344G in muscle had a neuropathy (n ϭ 25) (χ 2 TR ϭ 0.10, n.s.). Whereas 12.5% of individuals with 61-80% A8344G in muscle had ataxia (n ϭ 8), 80% of individuals with 91-100% A8344G in muscle had ataxia (n ϭ 25) (χ 2 TR ϭ 10.12, P ϭ 0.0015); and whereas 25% of individuals with 61-80% A8344G in muscle had myoclonus (n ϭ 8), 96% of individuals with 91-100% A8344G in muscle had myoclonus (n ϭ 25) (χ 2 TR ϭ 12.63, P ϭ 0.0004). Odds risk ratios were calculated for the clinical features which reached statistical significance with the χ 2 TR test. Individuals with Ͼ90% mutant mtDNA in muscle were 4.2 times more likely to have deafness (95% CI ϭ 1.44-12.02), 3.2 times more likely to have ataxia (95% CI ϭ 1.56 -6.55), and 2.6 times more likely to have myoclonus (95% CI ϭ 1.52 -4.30) than individuals with ഛ80% mutant mtDNA in muscle. The 95% CI of the odds ratio for the dementia data set included unity.
Discussion
We have studied 245 patients with mtDNA mutations who carried either the A3243G or the A8344G mutations. We have compared the frequency of specific clinical features associated with each mutation and have analysed the statistical relationship between the observed frequency of these features and the level of mutant mtDNA in muscle and blood.
Frequency of clinical features in A3243G MELAS and A8344G MERRF
Within this large study group, there is a clear difference in the frequency of specific clinical features associated with the A3243G and A8344G mutations. Although deafness, dementia, short stature and myopathy were commonly associated with both mtDNA mutations; recurrent strokes, CPEO, diabetes and pigmentary retinopathy were more often associated with the A3243G mutation. However, ataxia, myoclonus, neuropathy, optic atrophy and lipomata were more often associated with the A8344G mutation. Our findings thus confirm that these two mtDNA point mutations cause two distinct clinical syndromes which share certain features (DiMauro and Moraes, 1993; Wallace, 1995) . It is noteworthy that only 48% of the A3243G group had suffered recurrent strokes, and ataxia and myoclonus only occurred in 50% and 61%, respectively, of individuals with the A8344G mutation. Ataxia and myoclonus were also relatively common in individuals with the A3243G mutation (24% and 8%, respectively). On the basis of these results, the possibility of the A3243G mutation should not be dismissed in patients who have not experienced stroke-like episodes. Likewise, ataxia and myoclonus are by no means the only clinical features associated with A8344G, and screening for this mutation should be considered in patients with a broad range of abnormalities (Howell et al., 1996) .
Both the A3243G and A8344G mutations occur in mitochondrial tRNA genes. In vitro studies have shown that both mutations compromise mitochondrial respiratory chain function and that both are responsible for impaired mitochondrial protein synthesis (Chomyn et al., 1991; Kobayashi et al., 1991; Boulet et al., 1992; King et al., 1992) . Despite these similarities, A3243G and A8344G are associated with distinct clinical phenotypes. For example, we observed a striking difference in the ocular manifestations of these two mutations; pigmentary retinopathy was specifically associated with A3243G, whereas optic atrophy was predominantly associated with A8344G. Although these differences may arise as a consequence of differential segregation or proliferation of mutant mtDNA (Macmillan et al., 1993) , it is also possible that they are a more direct phenotypic consequence of the two tRNA mutations on different tissues and organs. Both mutations impair mitochondrial biogenesis, and, as a result, the function of the mitochondrial respiratory chain. However, different molecular mechanisms may be responsible for the expression of the A3243G and the A8344G mutations (Enriquez et al., 1995; Kaufmann et al., 1996) . It is thus possible that, given a specific mutant load, the two mutations will impair mitochondrial biogenesis to differing degrees in different cell types within different tissues. For example, the regulation of mitochondrial biogenesis in the retinal ganglion cell layer may be more sensitive to the phenotypic effects of the A8344G mutation, whereas the retinal pigment epithelium may be relatively more disrupted by the A3243G mutation. If this were so, it would explain the higher frequency of optic atrophy in patients with the A8344G mutation, and the higher frequency of pigmentary retinopathy in patients harbouring the A3243G mutation. Detailed studies of mutant load within specific cell subtypes and their correlation with the clinical features and pathology may help to resolve these issues.
Clinical expression and mutant load
There was a clear relationship between the level of mutant mtDNA in muscle and the frequency of the more common clinical features for both the A3243G and A8344G mutation. In sharp contrast, we did not observe any relationship with the level of either mutation in blood (leucocyte/platelet fraction). It is well recognized that patients harbouring A3243G usually have higher levels of mutant mtDNA in muscle than in rapidly dividing tissues such as blood. For this reason, one would not expect a close correlation between the level of A3243G in blood and clinical phenotype. However, individuals with A8344G often have similar levels of mutant mtDNA in both muscle and blood. Since we identified only 25 cases where the level of mutant mtDNA had been quantified in blood, it is likely that this subgroup was too small to allow the identification of a clear relationship between the A8344G levels in blood and the frequency of major clinical features. Therefore, in contrast to the A3243G mutation, we cannot interpret our findings as unequivocal evidence against a relationship between the A8344G mutation load in blood and the clinical phenotype. A number of the relationships between the level of A8344G in muscle and the frequency of clinical features did not reach statistical significance (myopathy, epilepsy and neuropathy). In each one of these cases, however, the overall trend conformed to significant trends seen with the other variables: higher levels of mutant mtDNA in muscle were associated with an increased frequency of clinical features. Similarly, for two of the odds ratios (deafness for A3243G and dementia for A8344G) the 95% CIs included unity.
At first sight there appears to be a discrepancy between the 85% threshold for the biochemical expression of mutant mtDNA in vitro and the threshold for the clinical expression in vivo. This disparity is probably a result of the cellular mosaicism of mutant mtDNA levels (Macmillan et al., 1993) . The optimal function of any organ is dependent upon the interaction of numerous cells, be they myocytes, pancreatic beta cells or neurons. Dysfunction of a small group of interacting cells may thus lead to organ failure, and although the levels of mutant mtDNA may be high in the malfunctioning cells, the mean tissue level may be low. Hence, individuals with Ͻ60% mutant mtDNA in central nervous tissue (and hence in skeletal muscle) may have a profoundly disabling neurological syndrome. Our observations highlight the discrepancy between cellular mtDNA thresholds for the expression of a cellular biochemical defect in vitro and the mean tissue mtDNA threshold for the clinical expression of mitochondrial disease in vivo.
Previous studies have shown that the level of mutant mtDNA in muscle resembles levels in central neurons (Ciafaloni et al., 1991; Macmillan et al., 1993; Tanno et al., 1993) ; it is not surprising, therefore, that for both the A3243G and the A8344G mutations, the frequency of central neurological (CNS) complications was greater for individuals with higher levels of mutant mtDNA in muscle. However, it is particularly interesting, and counter-intuitive, that myopathy, CPEO, and deafness are less frequent in individuals with greater levels of A3243G in muscle. In part, this apparent paradox may be due to difficulties in the clinical assessment of patients with advanced stroke disease (which affects to 73% of A3243G cases with Ͼ90% mutant mtDNA in muscle) and/or to a confounding effect of patient age. Although patients with a high level of A3243G in muscle had a lower mean age than those with less mutant mtDNA in muscle (Fig. 2B) , using age-corrected levels of A3243G in muscle did not alter the prevailing trend seen in this data set; higher levels of A3243G in muscle are associated with a reduced frequency of myopathy and CPEO (data not shown). This paradoxical pattern suggests that individuals with a high mutant load in muscle present at a young age with strokelike episodes, whereas those with a low mutant load present in later years with myopathy and external ophthalmoplegia and deafness.
Other studies have also highlighted the clinical and molecular differences between patients with A3243G who present with either CPEO or myopathy and those who present with stroke-like episodes (Martinuzzi et al., 1992; Moraes et al., 1993; Petruzzella et al., 1994; Hammans et al., 1995) . CPEO/myopathy is usually associated with a high percentage of cytochrome oxidase-negative fibres on muscle histochemistry, but low levels of A3243G measured in a skeletal muscle homogenate. In contrast, cytochrome oxidasenegative fibres are infrequent in patients who experience stroke-like episodes, but the mean level of A3243G in muscle is generally high (Moraes et al., 1993) . It has been suggested that CPEO occurs in patients with focal accumulations of mutant mtDNA in some muscle fibres (predominantly ragged red fibres), whereas stroke-like episodes occur in individuals with a much more uniform distribution of mutant mtDNA (Petruzzella et al., 1994) . Since the level of A3243G in muscle corresponds to the level in brain, it is possible that a similar pattern of distribution also exists within the CNS.
We have compared the level of mutation, at a particular time point, with the frequency of clinical features which were already present. This approach raises the question: is it possible to use this information to give prognostic advice? Various studies, each containing a small number of patients, have shown that the level of mutant mtDNA may increase (Mariotti et al., 1995) or decrease ('t Hart et al., 1996) during an individual's lifetime. We studied the relationships between age and mutation load in blood and muscle in the data set reported in this paper. Multivariate logistic regression analysis confirmed that mutation load was the best predictor of clinical phenotype and not the age of the individual (P. F. Chinnery, N. Howell, R. N. Lightowlers and D. M. Turnbull, unpublished results). Since we have shown that the level of mutation is correlated with the frequency of the clinical features, the observations reported in this manuscript can be used to guide prognosis.
The retrospective analysis of symptoms and signs is likely to lead to an under-estimation of the frequency of some clinical features. However, the effects of incomplete case ascertainment are likely to be minimal (P. F. Chinnery, N. Howell, R. N. Lightowlers and D. M. Turnbull, unpublished results). Similarly, although the precise methods of clinical and laboratory assessment may differ slightly between different centres (including the precise timing of a muscle biopsy or blood sample and the duration of follow up), we chose simple, categorical clinical criteria to minimize this effect, and it is unlikely that different methods for measuring mutant load could have exerted a major influence of the patterns that we have observed. Marked bias along these lines is also unlikely because the studies reported in this paper are in general agreement with one another. It would be of great interest to grade the severity of individual clinical features and to study the relationship between clinical severity and mutant load. A study such as that clearly could not be performed through a retrospective literature review, and it will take many years for any one centre to accumulate sufficient data to perform a prospective analysis. Despite the potential confounding effects, the results reported here reached a high level of statistical significance. This study thus provides a legitimate overview and is the most comprehensive that is presently available.
The incidence of the major clinical features associated with the A3243G and A8344G mutations are correlated to level of mutant mtDNA in skeletal muscle. As a consequence, it is possible to predict the incidence of these features by measuring mutant mtDNA levels is muscle. Providing the level of mutant mtDNA does not vary significantly during a patient's lifetime, these results may be used to provide prognostic information to patients who harbour these mutations. These results have far reaching implications; they will allow research to focus on certain high-risk subgroups when designing specific treatments for mtDNA defects, and they also suggest that gene therapy which reduces mutant load will have a direct effect upon clinical expression. In addition, these results will improve our ability to plan the future medical care of patients with these disorders.
